ライフサイエンスコーパス: drotrecogin alfa

1 an intravenous infusion of either placebo or drotrecogin alfa activated (24 microg per kilogram of bo

2 idence of serious bleeding was higher in the drotrecogin alfa activated group than in the placebo gro

3 ted (840 in the placebo group and 850 in the drotrecogin alfa activated group).

4 in the placebo group and 24.7 percent in the drotrecogin alfa activated group.

5 However, the safety of drotrecogin alfa activated has not been evaluated in lun

6 We report for the first time on the use of drotrecogin alfa activated in six lung transplant recipi

7 are warranted to further evaluate the use of drotrecogin alfa activated in transplant recipients.

8 In a previous study, drotrecogin alfa activated produced dose-dependent reduc

9 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death fro

10 Treatment with drotrecogin alfa activated significantly reduces mortali

11 ely defined primary analysis, treatment with drotrecogin alfa activated was associated with a reducti

12 A decade after drotrecogin alfa (activated) (DAA) was released on the m

13 Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had

14 istics and outcomes of patients treated with drotrecogin alfa (activated) (DrotAA) in clinical practi

15 Drotrecogin alfa (activated) (DrotAA) is used for the tr

16 of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment

17 Either 24 microg x kg x hr drotrecogin alfa (activated) (n = 3063) or placebo (n =

18 Key clinical trials involving drotrecogin alfa (activated) (or recombinant human activ

19 Drotrecogin alfa (activated) (Xigris) 24 microg/kg/hr fo

20 the magnitude of the treatment benefit with drotrecogin alfa (activated) across the underlying predi

21 Drotrecogin alfa (activated) acts as a modulator of nucl

22 e report observed 28-day mortality rates for drotrecogin alfa (activated) and placebo patients for su

23 ent Food and Drug Administration approval of drotrecogin alfa (activated) and the potential of severa

24 Hospital mortality was reduced by 18% with drotrecogin alfa (activated) compared with controls (rel

25 Actual mortality rates were lower with drotrecogin alfa (activated) compared with placebo for n

26 Thus, drotrecogin alfa (activated) cost $160,000 per life save

27 Drotrecogin alfa (activated) cost $27,400 per quality-ad

28 Thus, drotrecogin alfa (activated) cost $48,800 per quality-ad

29 Treatment of this disorder with drotrecogin alfa (activated) directly addresses these de

30 Drotrecogin alfa (activated) has anti-inflammatory, anti

31 Because drotrecogin alfa (activated) has anticoagulant propertie

32 In these subjects, drotrecogin alfa (activated) has minimal effects on meas

33 s for experimental and analytical studies of drotrecogin alfa (activated) in adults with severe sepsi

34 , and actual mortality rates were lower with drotrecogin alfa (activated) in all subgroups defined by

35 ts, provides evidence to support the role of drotrecogin alfa (activated) in modulating nuclear facto

36 ger absolute risk reductions were found with drotrecogin alfa (activated) in patients with a higher b

37 er the first 28 days (short-term Base Case), drotrecogin alfa (activated) increased the costs of care

38 ected to lifetime (lifetime Reference Case), drotrecogin alfa (activated) increased the costs of care

39 articipated in placebo-controlled studies of drotrecogin alfa (activated) infusion before an intraven

40 ed as an example of the protective effect of drotrecogin alfa (activated) on endothelial and mononucl

41 Drotrecogin alfa (activated) produces a robust reduction

42 The administration of drotrecogin alfa (activated) to patients with severe sep

43 ious bleeding or thrombotic event rates with drotrecogin alfa (activated) treatment between heterozyg

44 zygous carriers and non-Leiden carriers with drotrecogin alfa (activated) treatment were 20.3% and 24

45 erive similar benefit and risk profiles from drotrecogin alfa (activated) treatment.

46 spital mortality for single-group studies of drotrecogin alfa (activated) was 41% (95% CI 35-48), and

47 The serious bleeding rate with drotrecogin alfa (activated) was 5.6% (4.5-6.9), which w

48 Drotrecogin alfa (activated) was approved for use in sev

49 Drotrecogin alfa (activated) was the first biological tr

50 Metaregression showed greater benefits of drotrecogin alfa (activated) with increasing control mor

51 propose a broad anti-inflammatory effect of drotrecogin alfa (activated), acting on both endothelium

52 stasis, and activated recombinant protein C, drotrecogin alfa (activated), has been shown to reduce m

53 Drotrecogin alfa (activated), or recombinant human activ

54 demonstrate initial success with the use of drotrecogin alfa (activated).

55 ath and the risk of bleeding associated with drotrecogin alfa (activated).

56 risk reduction in 28-day mortality rates for drotrecogin alfa (activated).

57 Drotrecogin alfa (activated, human activated protein C)

58 from recombinant human activated protein C (drotrecogin alfa [activated]) as non-factor V Leiden car

59 Recombinant human activated protein C (drotrecogin alfa [activated]) has been approved for use

60 To date, only APC (drotrecogin alfa [activated]) has been shown to reduce m

61 d ENHANCE (a single-arm, open-label study of drotrecogin alfa [activated]) studies are reported here.

62 Recombinant human activated protein C (drotrecogin alfa [activated]) was successful as an inter

63 ating recombinant human activated protein C (drotrecogin alfa [activated]).

64 rotective ventilation, and consideration for drotrecogin alfa and steroid therapy.

65 Drotrecogin alfa has a cost-effectiveness profile simila

66 rial, recombinant human activated protein C (drotrecogin alfa) reduced mortality in patients with sev

67 al antibiotics, early goal-directed therapy, drotrecogin alfa, steroids, intensive insulin therapy, a